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OBJECTIVE — The purpose of this study was to determine whether multidisciplinary team-
based care guided by the chronic care model can reduce medical payments and improve quality
for Medicaid enrollees with diabetes.
RESEARCH DESIGN AND METHODS — This study was a difference-in-differences
analysis comparing Medicaid patients with diabetes who received team-based care versus those
who did not. Team-based care was provided to patients treated at CareSouth, a multisite rural
federally qualiﬁed community health center located in South Carolina. Control patients were
matched to team care patients using propensity score techniques. Financial outcomes compared
Medicaid (and Medicare for dually eligible patients) payments 1 year before and after interven-
tion.TrendsovertimeinlevelsofA1C,BMI,andsystolicbloodpressure(SBP)wereanalyzedfor
intervention patients during the postintervention period.
RESULTS — Although average claims payments increased for both the CareSouth patients
and control patients, there were no statistically signiﬁcant differences in total payments between
the two groups. In the intervention group, patients with A1C 9 at baseline experienced an
averagereductionof0.75mg/dlperyear(95%CI0.50–0.99),patientswithBMI30atbaseline
had an average reduction of 2.3 points per year (95% CI 0.99–3.58), and patients with SBP
140 mmHg at baseline had an average reduction of 2.2 mmHg per year (95% CI 0.44–3.88).
CONCLUSIONS — Team-based care following the chronic care model has the potential to
improve quality without increasing payments. Short-term savings were not evident and should
not be assumed when designing programs.
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T
he Institute of Medicine has cited
the growing prevalence of individu-
als with chronic conditions and de-
ﬁciencies in chronic care management as
two of the biggest challenges facing the
U.S. health care system (1). Individuals
with chronic conditions account for dis-
proportionatelyhighhealthcarecosts,of-
tenexperiencelossesinproductivity,and,
on average, receive only 56% of recom-
mendedcare(2–4).Healthcareorganiza-
tions increasingly have implemented
quality improvement strategies targeted
at better management of chronic condi-
tions.Thestrategiesgenerallyfallintotwo
categories: ﬁrst, the chronic care model
(CCM) advocates redesign of care delivery
at the practitioner level using evidence-
based guidelines, multidisciplinary treat-
ment teams, decision support systems,
and planned visits (5); and second, dis-
ease management, typically implemented
through health plans (either directly or
via disease management vendors), pro-
vides primarily telephonic interactions
via remotely located nurses with the ob-
jective of improving patients’ self-
management skills (6). In contrast to the
CCMapproach,whichadvocatesdelivery
system redesign, disease management is
primarily a means of supplementing care
provided in physician’s ofﬁces (7).
Multiple studies have documented
the effectiveness of CCM- and disease
management–based strategies in improv-
ing quality of care (8–10). Advocates of
quality improvement strategies have hy-
pothesized that improvements in chronic
care management could also result in ﬁ-
nancial beneﬁts through the prevention
or delay of expensive complications (11).
However, results from empirical studies
examining cost savings from CCM and
disease management programs have been
inconclusive (12–16). The evidence sug-
gests that although quality improvement
initiatives have the potential to result in
better quality of care, it is uncertain
whether these strategies will lead to lower
costs. Given the substantial ﬁnancial bur-
den imposed by chronic conditions on
patients, payers, and employers, assess-
ment of the ﬁnancial impact of chronic
caremanagementstrategiesremainsakey
health policy issue.
In1998theBureauofPrimaryHealth
Care, began a 6-year effort, known as the
Health Disparities Collaboratives, to im-
prove the quality of care in federally qual-
iﬁed community health center (FQHCs)
(17). As part of this initiative, the federal
government provided funds and techni-
cal assistance to FQHCs to implement
team-based, patient-centered, primary
care to individuals with chronic condi-
tions. The initiative included “Break-
through Series” training programs for
clinic personnel provided by the Institute
for Healthcare Improvement, in conjunc-
tion with the Improving Chronic Illness
Care organization (18,19). The Break-
through Series targets redesign of a pro-
vider’s delivery system to be consistent
withtheCCMbyuseofarapidcyclequal-
ity improvement process (Plan, Do,
Study, Act). CareSouth, a private non-
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care services in 10 clinics in and around
Hartsville, South Carolina, was an early
participantinthisprogramandbeganim-
plementation in 1999. The objective of
our study was to assess the impact of
CareSouth’s program on short-term Med-
icaid payments (and also Medicare pay-
ments for beneﬁciaries with dual
eligibility) and on key clinical diabetes
indicators.
RESEARCH DESIGN AND
METHODS
Clinical intervention
CareSouth serves 35,000 patients in an
area that is rural, predominantly low in-
come,AfricanAmerican,andelderly.The
intervention used collaborative team-
based treatment with teams comprising a
physicianornursepractitioner,careman-
ager (RN or LPN), medical assistant, in-
formation specialist, and a part-time
social worker. To facilitate continuity of
care,patientsareassignedtospeciﬁcteams.
Guidedbyevidence-basedtreatmentproto-
cols,theteamsprovidecareviaplannedvis-
its capitalizing on the relevant expertise of
eachteammember(20).Inadditiontopro-
viding medical management, the teams en-
courage and facilitate patient self-
management. The staff also provides
telephonesupporttoanswerpatients’ques-
tions and check on their progress.
TheinterventionincorporatestheBu-
reauofPrimaryHealthCare-providedPa-
tient Evaluation and Care System (PECS)
patient registry system, which captures
key clinical and administrative informa-
tion at the patient level and is available to
clinicians at the point of service. The sys-
tem prompts key guideline requirements
to practitioners (e.g., screening for A1C),
provides up-to-date test results, and facil-
itates planned visits addressing multiple
diseases, including asthma, cardiovascu-
lar disease, depression, and diabetes.
CareSouth’s program was pilot tested in
one site in 1999 and gradually rolled out
to their remaining clinics over 4 years.
Data
We obtained all Medicaid claims between
1997 and 2005 for individuals with ICD-
9-CM codes of 250.x0 and 250.x2 indi-
cating type 2 diabetes as a primary or
secondarydiagnosisfromtheSouthCaro-
lina Ofﬁce of Research and Statistics. Of
the CareSouth patients, 43% had dual el-
igibility for Medicaid and Medicare, and
we also obtained Medicare payment data
from the South Carolina Ofﬁce of Re-
searchandStatisticsfortheduallyeligible
patients. Patients in the CareSouth pro-
gram were compared with control pa-
tients who were Medicaid and dually
eligible patients from similar FQHCs lo-
cated in South Carolina that had not con-
verted to team-based care during the
study period. Information about the
mode of care delivery within FQHCs
(team-based or conventional) was ob-
tained from the South Carolina Primary
Health Care Association. Laboratory val-
ues from serial measurements of A1C,
SBP, and BMI were acquired from the
CareSouth PECS registry. However, be-
cause PECS was implemented at the start
of the intervention, clinical data were
availableonlyforCareSouthpatientsdur-
ing the postintervention period. Compar-
ative information was not available from
control sites.
Our primary outcome variable for
the ﬁnancial analysis was the difference
between 1-year costs before and after
the start of the intervention. Therefore,
to be included in the analysis, individuals
wererequiredtobecontinuouslyenrolled
in Medicaid during the entire pre- and
postperiodsandtohavehadadiagnosisof
diabetes, deﬁned as a claim with an ICD-
9-CMcodefordiabetes,beforethestartof
the preperiod. The intention of the latter
criterionwastoincludeonlypatientswho
were receiving treatment for diabetes in
both the pre- and postperiods. Because
entry of registry data only commences
when a CareSouth patient begins partici-
pation in team care, we used each pa-
tient’s initial date of registry data as the
starting point of the intervention.
We identiﬁed 2,572 patients with
type 2 diabetes in the CareSouth registry.
Of these, 621 had a Medicaid claim at a
CareSouth clinic. Limiting these to pa-
tients who were continuously enrolled in
Medicaidduringthepre-andpostperiods
reducedthesampleofCareSouthpatients
to 399. Further restricting the sample to
patients in whom diabetes was diagnosed
1 year before the start date of the inter-
vention yielded 199 patients meeting all
inclusion criteria. We identiﬁed 43,133
potential control patients with type 2 di-
abetes among Medicaid claims. Of these,
36,213 were eligible for Medicaid
throughoutthepre-andpostperiods,and
only 8,179 had at least one clinic visit.
Limiting eligibility to patients with a
clinicvisittoaFQHCwithoutteam-based
care reduced the sample to 3,140, and
furtherrestrictiontopatientsinwhomdi-
abetes was diagnosed 1 year before the
startdateoftheinterventionyieldedapo-
tential sample of 1,868 control patients.
Propensity score matching
There were differences between the 199
patients treated at CareSouth clinics and
the other 1,868 Medicaid patients used as
controlpatients.Ourinitialanalysisofpa-
tient characteristics showed that Care-
South patients were typically older than
control patients (P  0.0001), were less
likelytobeAfricanAmerican(P0.001),
and had more severe comorbidities (P 
0.0007) as measured by the Charlson Co-
morbidity Index (21,22). To control for
these differences, we further reﬁned our se-
lection of control patients using propensity
score matching. Patients were matched on
the following characteristics: age, sex, race,
dual eligibility, use of antidepressants, and
the Charlson Comorbidity Index.
The propensity score matching pro-
ceeded in two steps. In the ﬁrst step, the
likelihood of being a CareSouth patient
was modeled in a logistic regression as a
function of the characteristics described
previously. From this regression, the pre-
dicted probability, or propensity score,
was computed for each patient. Given the
relatively small number of CareSouth pa-
tients,weselectedcontrolpatientsusinga
nearest neighbor matching method,
which selects a control patient who has
the closest propensity score to the Care-
Southpatient(23).Matchingwasdoneby
clinic and without replacement, and we
choseonlyonecontrolpatientperpatient
to ensure balance in a way that is both
conservative and enhances the interpret-
ability of results. Once matched control
patientswereselected,weveriﬁedthatthe
distribution of covariates matched that of
the CareSouth patients. The ﬁnal sample
for the ﬁnancial analysis consisted of 193
CareSouth patients and 193 control pa-
tients. We were unable to ﬁnd matched
control patients for 6 CareSouth patients.
Analysis of ﬁnancial data
Our statistical analysis was designed to
compare total Medicaid payments for pa-
tients enrolled in the CareSouth program
to the propensity score-matched Medic-
aid patients who did not receive team-
based care. For patients who were dually
eligible, payments included the sum of
Medicaid and Medicare payments. Our
analysisincludedassessmentofbothtotal
payments and subcategories: inpatient
hospital payments, outpatient hospital
payments, nonhospital outpatient pay-
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cial data included the sum of Medicaid
payments plus Medicare payments for
dually eligible patients for 1 year before
and after the start of the intervention.
We then analyzed these payments for
matched CareSouth and control patients
using a “difference-in-differences” ap-
proach. This analysis compared the dif-
ferences in payments between year 1
(preintervention) and year 2 (postinter-
vention) in the CareSouth group with dif-
ferences between year 1 and year 2 in the
control group. Our hypothesis was that
patients in the CareSouth and control
groups had the same expected payments
before the intervention, but that there were
signiﬁcantdifferencesinpaymentsbetween
CareSouth and control patients after the in-
tervention. The difference-in-differences
model captures these effects. Our general-
ized linear regression model was
gEyit  0  1ti  2CSit 
3(CS   t)it (1)
where i indexes patients and t indexes the
time period. Thus, yit is total Medicaid
payments (plus Medicare payments for
dually eligible patients) and payments
broken down by category (e.g., inpatient,
pharmacy,andsoon).Aseq.1illustrates,
t is a binary variable that takes on a value
of 1 if the expenditure occurred in the
postintervention period, CSit is a binary
indicator variable for the CareSouth
group, and the coefﬁcient on the interac-
tionoftandCS,3,providesevidencefor
whether the post/predifference in total
paymentsbetweentheCareSouthandthe
control group was signiﬁcantly different
from 0. The coefﬁcient on the interaction
term is the quantity of interest because it
represents the difference in expenditures
between pre- and postperiods for Care-
South patients and control patients. Fi-
nally, g is a link function for the
generalized linear model. Because the ex-
penditure data were highly skewed, as is
often the case when health expenditures
are examined, we ﬁt the data to a gener-
alized linear model, assuming a gamma
distribution and a log link function. Note
that the log link function transforms the
difference-in-differences to a ratio of ratios
andtheresultsareintermsofmultiplicative
effects of team care. Because patients were
matchedondemographicandclinicalchar-
acteristics,noadditionalcovariateswerein-
cluded in the model (24).
Analysis of clinical data
The objective of the statistical analysis
was to determine whether patients en-
rolled in the CareSouth program experi-
enced improvements in A1C, BMI, and
SBP over time. We modeled trends in
A1C, BMI, and SBP for the propensity
score-matched CareSouth patients in the
postintervention period only because
comparable data were not available for
the control group or for the CareSouth
patients before the intervention. In addi-
tion,notalloftheCareSouthpatientshad
measures beyond baseline. Therefore, the
number of patients studied in the SBP,
A1C, and BMI analyses were 193, 171,
and 67, respectively. The dependent vari-
ables were serial observations of the clin-
ical measures. Because these are repeated
measures,wecontrolledforclusteringus-
ingrandomeffects.Thecovariateofinter-
est was time, measured in days since the
ﬁrst laboratory result in the registry. We
also controlled for age, sex, and race.
CareSouth clinic location was controlled
for using clinic ﬁxed effects. The ﬁnal
model was as follows:
mit  0  1t  2xit  3zi  i  ε it
(2)
where i indexes patients and t indexes
time (measured in days from the ﬁrst
measurement in the registry), mit is a clin-
ical measure for patient i in time t, xit is a
vector of patient characteristics (age, sex,
and race), zi is a vector of CareSouth clin-
ics, i is a zero-mean, normally distrib-
utedrandomeffect,andε itisazero-mean,
normally distributed error term. For this
analysis we ﬁrst studied all CareSouth pa-
tientswithtwomoremeasurementsasde-
scribed above. We then repeated the
analysis using only those patients whose
baseline measures were particularly high,
deﬁned as A1C 9, BMI 30, and SBP
140.
RESULTS
Financial data
Our analysis showed that average 1-year
payments at baseline were signiﬁcantly
lower for CareSouth patients for nonhos-
pital-basedoutpatientcare($2,096.60vs.
$2,940.80, P 	 0.025) and signiﬁcantly
higher for hospital-based outpatient care
($445.70 vs. $260.50, P 	 0.012) (Table
1). Differences in other subcategories of
payments were not statistically signiﬁ-
cant, either at baseline or after the inter-
vention (Table 1). For CareSouth
patients, average 1-year payments before
and after the intervention rose in the
postintervention period for all types of
care except hospital-based outpatient
care; for control patients, these payments
rose for all types of care except inpatient
care (Table 1). Figure 1 presents the esti-
mates and CIs of the parameters in the
difference-in-differences regressions.
None of the differences noted were statis-
tically signiﬁcant except for hospital-
Table 1—Medicaid and Medicare payments in CareSouth patients versus matched control patients before and after implementation of team
care by cost category
Before intervention After intervention
CareSouth Control P value CareSouth Control P value
Inpatient care 1,230.26 
 3,623.82 1,611.06 
 5,336.316 0.4126 1,470.85 
 5,340.159 1,567.21 
 5,320.329 0.8591
Nonhospital
outpatient care
2,096.63 
 3,104.133 2,940.78 
 4,335.243 0.0254 3,022.65 
 5,695.479 3,490.40 
 6,034.75 0.4341
Hospital outpatient
care
445.65 
 915.4637 260.50 
 457.4701 0.0124 280.40 
 584.9204 281.64 
 477.1866 0.9818
Pharmacy 2,479.20 
 2,091.833 2,499.67 
 2,290.305 0.9270 2,709.67 
 2,223.474 2,887.51 
 2,742.313 0.4845
Total 6,251.74 
 6,648.942 7,312.01 
 8,748.297 0.1809 7,483.57 
 9,834.168 8,226.76 
 10,512.23 0.4737
Data are means 
 SD in USD.
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signiﬁcantly lower for the CareSouth
group. However, the apparent advantage
ofteamcareinthiscategoryresultedfrom
differences in preintervention rather than
postintervention costs.
Clinical data
Results in Fig. 2 suggest that among all
CareSouth patients, A1C did not change
signiﬁcantly over time, but among pa-
tientswithabaselineA1C9mg/dl,A1C
decreased signiﬁcantly over time. For this
subset, the average 
 SD baseline A1C
was 9.75 
 2.25 mg/dl and fell 0.75
mg/dl per year (P  0.0001). CareSouth
patientshadastartingBMIof35.0
10.4
kg/m
2 and experienced an average de-
crease of 1.9 points per year (P 
0.0001). Among CareSouth patients with
a starting BMI 30 kg/m
2 (40.1 
 9.5),
BMI fell 2.3 points per year (P 	
0.001). Similarly, among all CareSouth
patients, SBP decreased signiﬁcantly over
time (0.88 mmHg per year, P 	 0.014)
and patients with a baseline SBP 140
mmHg also had a signiﬁcant drop in
blood pressure over time (2.2 mmHg
per year, P 	 0.035).
CONCLUSIONS — Our analysis
suggests that patients enrolled in the
CareSouth program did not experience
signiﬁcantly lower total Medicaid and
Medicare expenditures than similar pa-
tients who did not receive team-based
care. These results were true for speciﬁc
cost categories as well, except for hospi-
tal-based outpatient visits, for which
there was a small but statistically signiﬁ-
cant reduction for CareSouth patients.
The results are consistent with ﬁndings
from prior studies using less rigorous de-
signs. Our analysis demonstrated clini-
cally and statistically signiﬁcant
improvement over time in A1C, BMI, and
SBP for the CareSouth patients, particu-
larlyforthosepatientsstartingwithworse
baseline levels. However, because of a
lack of data availability, as described
above, we were not able to measure clin-
ical improvements relative to the control
group.Nonetheless,themagnitudeofour
estimates for the clinical indicators is in
the range of those found in the literature
for similar interventions targeted at A1C
andSBPinpatientswithdiabetes(10,25).
The drop in the BMI, both across all pa-
tients and for patients with baseline val-
ues in the high range of this indicator, is
both clinically signiﬁcant and unusual.
The fact that care improved without
changes in drug costs is noteworthy. This
fact, coupled with improvement in BMI,
makes it reasonable to hypothesize that
better lifestyle management may have
been the big driver.
Although we were unable to measure
the intensity of the implementation of
their quality strategies, CareSouth’s inter-
vention incorporated key elements of the
CCM including a patient registry, patient
education, facilitation of self-manage-
ment skills, and, perhaps most impor-
tantly, the use of multidisciplinary teams.
A meta-analysis by Shojania et al. (10),
comparing the most commonly used
strategies targeted at reducing glycemic
levels in individuals with diabetes,
showedthatinterventionsusingmultidis-
ciplinary teams were the most effective.
As with all studies in this area, ours is
subject to several important limitations.
First, we did not have detailed clinical
datafortheCareSouthpatientsinthepre-
period or for the control group in either
the pre- or postperiods. This is not un-
usual, as these data typically are collected
only when an intervention has begun.
Second, our study may be underpowered
todetectdifferencesintheannualcostsof
medical care for patients with diabetes.
This is an important limitation and raises
the possibility that real savings from
team-based care may not be detectable
owing to chance, given our small sample
Figure 1—Differences between CareSouth patients and control subjects in changes of annual payments from the year before the interventions to the
year after. The black boxes represent the point estimates of the difference in differences, and the lines represent the CIs of the parameters.
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strictions,whicharedesignedtoidentifya
meaningful intervention sample, reduce
the overall size of the analytic sample.
Third, our study only examined costs for
1 year after implementation of the inter-
vention at the CareSouth clinics. Selby et
al. (26) provided a conceptual discussion
regarding the returns to managing diabe-
tes care and concluded that if returns are
likely, they may not be realized until well
into the future. A multiyear study by
Wagneretal.(27)thatcomparedpatients
with diabetes who achieve sustained de-
creases in A1C levels (i.e., a reduction of
1 percentage point) with patients who
did not show improvement, noted that
savings in total health care costs did not
occur until the second year of the study.
Unfortunately,ourstudydidnothavethe
data to follow the sample beyond 1 year,
so we cannot rule out the possibility that
the CareSouth patients might be less
costly over the long run.
Finally, our sampling inclusion crite-
ria mandated continuous Medicaid en-
rollment for 1 year after the intervention.
Unfortunately, we were not able to iden-
tify the reasons for patients dropping out
of the Medicaid program and conse-
quently may have excluded individuals
who died during the intervention. This
factor could have an impact on the results
if the distribution of exclusions due to
deathswassigniﬁcantlydifferentbetween
CareSouth and control patients.
Despite these limitations, we believe
that our study advances the scant litera-
tureintheareaoftheﬁnancialandclinical
impact of care management programs for
diabetes. The strength of our study, rela-
tive to the existing literature, is the de-
tailed control strategy to allow for
comparisons with the intervention group
in the ﬁnancial analysis. And although we
cannot rule out the possibility of longer-
term savings associated with these pro-
grams,thefactthatimmediatesavingsare
not found is an important message for
policy makers and purchasers (including
those in the Medicaid and Medicare pro-
grams) who often believe that shorter-
term savings are likely.
We should note that CareSouth’s
motivation for this initiative was quality
improvement rather than cost reduction.
Value in health care often is deﬁned as
cost/quality. Under ideal circumstances,
costs would decrease and quality would
improve. However, greater value also can
be achieved if either the numerator or the
denominator changes in the appropriate
direction. Pressure to constrain rising
health care costs may cause purchasers
andpolicymakerstoplaceundueempha-
sis on the cost-saving potential of chronic
care management strategies. However,
until deﬁnitive evidence regarding cost
implicationsbecomesavailable,perhapsa
more realistic perspective is warranted.
Our ﬁndings suggest that although short-
term savings are unlikely, the proverbial
glass may, in fact, be half full. Even if
longer-term savings do not materialize,
theﬁndingsdosuggestthatpayers,inthis
case Medicaid and Medicare, received
greater value for their dollars in the Care-
South sites after the intervention. Never-
theless, future researchers should seek to
follow control and treatment groups for
extended periods to provide better evi-
dence on whether there is a return on in-
vestment associated with these programs
over time.
Acknowledgments— This research was sup-
ported by a grant from the California Health-
Care Foundation.
We are grateful to Sophia Chang, our
project ofﬁcer, for useful feedback and to the
following individuals for providing the study
data and background information about Care-
South and the South Carolina Medicaid pro-
gram: Ann Lewis, Heather Kirby, Kevin
Rogers, and Lathran Woodard.
Figure 2—Summary of trends in clinical measures among CareSouth patients, adjusted for demographics, comorbidities, and patient level cluster-
ing. *P  0.05; **P  0.01; ***P  0.0001. Patients with two, three, or four (or more) observations of BMI were 28, 12, and 27, respectively.
Comparable numbers for A1C were 35, 28, and 108 and for SPB 11, 15, and 167.
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